Navigation Links
Study of Drug Therapy for Compulsive Buying Yields a Puzzle,,Stanford Researcher Says

STANFORD, Calif.--(BUSINESS WIRE)--Mar 14, 2007 - Researchers at the Stanford University School of Medicine say they are puzzled by findings from their new study indicating that an antidepressant, which previously showed promise in treating a behavioral disorder known as compulsive buying, did not result in a sustained benefit for the patients who took it.

The medication is escitalopram, a commonly prescribed antidepressant sold under the brand name Lexapro. In the study, researchers found no difference in the relapse rate of people with compulsive-buying disorder when they continued to take escitalopram compared with those who had been switched to a placebo. Those results are perplexing to lead author Lorrin Koran, MD, professor of psychiatry and behavioral sciences emeritus, because he had done a similar study in 2003 that found compulsive-buying patients improved stably after taking another antidepressant medication, citalopram, in which escitalopram is the active ingredient.

"It was a shock that, when we did the trial again with the active ingredient, it didn't work exactly the same way. It should have," said Koran, who also led the 2003 study. The results of the latest double-blind, placebo-controlled trial will be published in the April issue of the Journal of Clinical Psychopharmacology.

Koran said the unexpected result from the new study may in part be due to the small number of participants in the double-blind phase of the trial, which involved just 17 subjects whose buying behavior had markedly improved in the initial stage of the trial when they were all taking escitalopram. Of the nine randomly assigned to take a placebo in the later part of the trial, six relapsed, while five of eight continuing on escitalopram relapsed.

But the study size is likely not the only factor influencing the outcome of the trial.

"I don't think we're dealing with one pure biological disorder,"
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/1/2014)... JUPITER, Fla. , Oct. 1, 2014 /PRNewswire/ ... biotechnology company with patented and proprietary technology used ... for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial ... $500,000 licensing payment from Abengoa Bioenergy for commercial ... for converting biomass into ethanol, developed under Abengoa,s ...
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, ... diagnostics, announced today that Eli Diamond , ... Cancer Center (MSK), presented clinical data from an ... cancer monitoring platform for the determination of oncogene ... liquid biopsy.  The results were presented to both ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... (Nasdaq: BIOD ) announced today that the ... development programs have been accepted for poster presentation at ... November 11 and 12, 2010: "Characterization of ... presented by Dr. Frank Flacke, November 12 ...
... -- WuXi PharmaTech (NYSE: WX ), ... and development outsourcing company with operations in China ... had been awarded a Certificate of Good Laboratory ... Drug Administration (SFDA), China,s regulatory authority for pharmaceuticals, ...
Cached Medicine Technology:Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 2Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 3Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting 4WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility 2
(Date:10/1/2014)... (PRWEB) October 01, 2014 Lifeinsurance-policy.com ... find the best life insurance prices for smokers. , ... life insurance premiums. Comparing quotes is the best method ... finding quotes for customers who need coverage. , ... entire duration of the policy. Since the coverage is ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... new genetic finding from Duke Medicine suggests that some ... might also be hard-wired to gain weight when exposed ... , An estimated 13 percent of people, all of ... knowing this could help them reduce heart disease with ... stress management. , "Genetic susceptibility, psychosocial stress and metabolic ...
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... October is Breast Cancer Awareness,Month, and while awareness ... an,all-time high, the percentage of women receiving regular ... Disease Control and,Prevention. Women should know that emerging ... maintain their long-term breast health. Listen to ...
... blood leaving the liver during chemotherapy could prolong the lives ... procedure allows massive doses of chemotherapy drugs to reach the ... of the body. , The regime involves injecting the drug ... divert the blood leaving it. This blood is then filtered ...
... Germany, Sept. 26 Ziehm,Imaging, a provider ... a manufacturer of software-driven systems for targeted,less-invasive ... agreement for the integration of mobile 3D ... 2002, Ziehm Imaging and BrainLAB jointly pioneered ...
... Small Disadvantaged ... Businesses, ... and GlaxoSmithKline (NYSE: GSK ) today announced,the results of a ... disadvantaged businesses (SDBs). Rep. Kendrick B. Meek (D-Fla.), chairman of ...
... at ADA,s Annual,Meeting Here, SAN FRANCISCO, Sept. 26 ... including heart,problems, diabetes and pneumonia make it even more ... a lifetime., According to a recent report from ... keeping their natural teeth longer well beyond,the age of ...
... BIRMINGHAM, Ala., Sept. 26 HealthSouth,Corporation (NYSE: HLS ... a regular quarterly dividend of $16.25 per share on ... October 15,2007, to holders of record on October 1, ... largest provider of inpatient,rehabilitation services. Operating in 27 states ...
Cached Medicine News:Health News:'Re-plumbing' liver helps beat cancer 2Health News:Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS) 2Health News:Revision: Ziehm Imaging and BrainLAB Announce Partnership for Intra-Operative 3D Imaging and Computer Assisted Surgery (CAS) 3Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 2Health News:Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results 3Health News:OralLongevity (TM) Program Targets Oral Health of Older Americans 2Health News:OralLongevity (TM) Program Targets Oral Health of Older Americans 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... Your patient will be more comfortable, ... tracheostomy tube stabilization more secure and to ... tying and untying of twill ties, consider ... adult and neonate/infant sizes, the narrow fastener ...
... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...
Medicine Products: